David Pelizzon Sells 22,500 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 22,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $23.35, for a total transaction of $525,375.00. Following the sale, the director owned 6,504,133 shares in the company, valued at $151,871,505.55. The trade was a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

OrthoPediatrics Price Performance

OrthoPediatrics stock opened at $22.41 on Friday. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The company has a fifty day simple moving average of $21.78 and a 200-day simple moving average of $18.87. The stock has a market cap of $585.13 million, a P/E ratio of -13.34 and a beta of 0.99. OrthoPediatrics Corp. has a 12-month low of $14.42 and a 12-month high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The company had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. Equities analysts expect that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on KIDS shares. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Piper Sandler reiterated an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. BTIG Research raised their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Finally, Truist Financial set a $22.00 target price on OrthoPediatrics in a research report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and an average target price of $26.44.

Hedge Funds Weigh In On OrthoPediatrics

Several hedge funds have recently bought and sold shares of KIDS. Russell Investments Group Ltd. boosted its position in OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of OrthoPediatrics in the second quarter valued at $34,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after buying an additional 2,561 shares during the last quarter. Caption Management LLC purchased a new stake in shares of OrthoPediatrics in the 3rd quarter worth about $54,000. Finally, BNP Paribas Financial Markets boosted its position in shares of OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after buying an additional 1,235 shares in the last quarter. 69.05% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.